Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study

Zhe Liu; Qin Wang; Na Li; Chunyu Xu; Yunpu Li; Jun Zhou; Liu Liu; Haijing Zhang; Yang Mo; Feng Han; Dongqun Xu

doi:10.3389/fpubh.2022.1082327

Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study

Front Public Health. 2023 Jan 9:10:1082327. doi: 10.3389/fpubh.2022.1082327. eCollection 2022.

Authors

Zhe Liu¹, Qin Wang¹, Na Li¹, Chunyu Xu¹, Yunpu Li¹, Jun Zhou¹, Liu Liu^{1

2}, Haijing Zhang¹, Yang Mo¹, Feng Han^{1

3}, Dongqun Xu¹

Affiliations

¹ China CDC Key Laboratory of Environment and Population Health, National Institute of Environmental Health, Chinese Center for Disease Control and Prevention, Beijing, China.
² Chaoyang District Center for Disease Control and Prevention, Beijing, China.
³ National Institute for Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing, China.

Abstract

Background: Exposure to PM_2.5 will accelerate the progression of cardiovascular diseases. Air purifier can reduce the PM_2.5 exposure and theoretically alleviate the influence of PM_2.5 on patients with stable coronary artery disease (SCAD). However, few studies of the protective effect showed significant results because the interferent effects of routine medication had not been taken into account. In order to explore the actual effect on patients with SCAD, we conducted a randomized single-blind crossover air purifier intervention trial.

Method: Levels of PM_2.5 exposure during intervention and cardiovascular indicators (inflammation, coagulation, plaque stability, and blood lipids) after intervention were detected, meanwhile the information of drug use was obtained by questionnaire. The kinds of drug used by more than 20% of the subjects were sorted out. And the influence of these drugs on cardiovascular indicators was summarized through literature review. Based on that, the drug use was included as a variable in linear mixed effects models that used to analyze the associations between PM_2.5 exposure reduction by air purifier and cardiovascular indicators.

Results: The result revealed that the interpretation contribution rate of drug use was more than that of PM_2.5 exposure. The level of C-reactive protein significantly decreased by 20.93% (95%CI: 6.56%, 33.10%), 23.44% (95%CI: 2.77%, 39.39%) and 24.11% (95%CI: 4.21%, 39.69%) on lag1, lag01 and lag02 respectively, while the level of high-density lipoprotein cholesterol significantly increased by 5.10% (95%CI: 0.69%, 9.05%), 3.71% (95%CI: 0.92%, 6.60%) and 6.48% (95%CI: 2.58%, 10.24%) respectively on lag0, lag1 and lag01 associated with an interquartile range decrease of 22.51 μg/m³ in PM_2.5 exposure.

Conclusion: The study shows positive effects of air purifier on SCAD, and also provides methodological reference for future related research.

Keywords: PM2.5; SCAD; air purifier; drug use; health protection; intervention trial.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Air Filters*
Air Pollutants* / analysis
Air Pollution* / analysis
Coronary Artery Disease*
Cross-Over Studies
Humans
Particulate Matter / analysis
Single-Blind Method

Substances

Air Pollutants
Particulate Matter

Grants and funding

This work was supported by the National Research Program for key issues in Air Pollution Control (DQGG0405).